COVID 19 in Antimicrobial and Antibacterial Agents

COVID-19  caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally Bacterial co-infections are correlated with unfavorable outcomes in respiratory viral infections. Despite, microbiological and antibiotic data related to COVID-19 are skimpy, competent use of antibiotics in line with antibiotic stewardship (ABS) principles is guaranteed during the pandemic. Bacterial and fungal co-infections are subtle in COVID-19 patients and are mainly ubiquitous in critically ill patients. In addition, studies are needed to estimate the impact of antimicrobial therapy on therapeutic outcomes in COVID-19 patients to prevent antimicrobial overuse. A novel beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was consequently identified as the causative pathogen. Ordinarily, respiratory viral infections are a risk factor for bacterial co-infections, which then increase disease austerity and mortality. It has been established that sepsis and ventilator-associated pneumonia are frequently observed complications in COVID-19 patients.

    Related Conference of COVID 19 in Antimicrobial and Antibacterial Agents

    September 06-07, 2021

    11th World Congress on Rare Diseases and Orphan Drugs

    Berlin, Germany
    September 13-14, 2021

    4th Global Experts Meeting on Infectious Diseases

    Singapore City, Singapore
    October 21-22, 2021

    International Conference on Tropical Diseases and Cure

    Zurich, Switzerland
    November 22-23, 2021

    3rd World Congress on Advancements in Tuberculosis and Lung Diseases

    Singapore City, Singapore
    February 07-08, 2022

    9th International Congress on Infectious Diseases

    Aberdeen, UK

    COVID 19 in Antimicrobial and Antibacterial Agents Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in